99mTechnetium-labeled cardiac scintigraphy for suspected amyloidosis: a review of current and future directions

Jean Michel Saad, Ahmed Ibrahim Ahmed, Yushui Han, Subha Saeed, Payam Pournazari, Mouaz H. Al-Mallah

Research output: Contribution to journalReview articlepeer-review

Abstract

Cardiac amyloidosis (CA) is an underdiagnosed form of restrictive cardiomyopathy leading to a rapid progression into heart failure. Evaluation of CA requires a multimodality approach making use of echocardiography, cardiac magnetic imaging, and nuclear imaging. Technetium (Tc)-labeled cardiac scintigraphy has witnessed a resurgence in its application for the workup of CA. Advancements in disease-modifying therapies have fueled the rapid adoption of cardiac scintigraphy using bone tracers and the need for transformative novel studies. The goal of this review is to present diagnostic utility, currently recommended protocols, as well as a glimpse into the rapid evolution of Tc-labeled cardiac scintigraphy in the diagnosis of CA.

Original languageEnglish (US)
JournalHeart Failure Reviews
DOIs
StateAccepted/In press - 2021

Keywords

  • Amyloidosis
  • ATTR
  • Nuclear
  • Quantification
  • Scintigraphy
  • SPECT

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Fingerprint

Dive into the research topics of '<sup>99m</sup>Technetium-labeled cardiac scintigraphy for suspected amyloidosis: a review of current and future directions'. Together they form a unique fingerprint.

Cite this